CJC-1295 + Ipamorelin Stack Research Guide 2026

The combination of CJC-1295 and Ipamorelin represents the most studied peptide stack in growth hormone secretagogue research. Their complementary mechanisms — GHRH receptor agonism and selective ghrelin receptor activation — produce synergistic GH pulses characterized across multiple research models.

Why These Two Compounds Are Studied Together

Natural GH release requires two simultaneous signals: a GHRH pulse activating pituitary somatotrophs via GHRH-R (Gαs/cAMP/PKA cascade), and a ghrelin signal amplifying the response via GHS-R1a (Gαq/PLC cascade). These are distinct receptors using distinct intracellular pathways.

CJC-1295 activates the first pathway. Ipamorelin activates the second. Administering both recreates the dual-signal requirement for maximal GH secretion from somatotrophs — producing pulse amplitudes documented to be significantly larger than either compound alone.

CJC-1295 Pharmacokinetics

CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes, producing a defined GH pulse before clearance. This short half-life is advantageous in research models designed to mimic physiological GH pulsatility.

CJC-1295 with DAC incorporates a Drug Affinity Complex enabling covalent albumin binding, extending half-life to 6-8 days. This produces sustained GHRH receptor activation and prolonged GH and IGF-1 elevation. Research using DAC form documented IGF-1 increases of 200-300% above baseline with weekly administration schedules.

Ipamorelin Pharmacokinetics

Ipamorelin has a half-life of approximately 2 hours. Its defining research characteristic is receptor selectivity — among all synthetic GHRPs studied, ipamorelin demonstrates the narrowest selectivity for GHS-R1a without significant cortisol, prolactin, or ACTH elevation at research doses. This clean profile made it the preferred GHRP partner for CJC-1295 in research models where cortisol interference must be minimized.

Published Protocol Models

The most referenced research protocol for the No-DAC combination involves administration timed to coincide with post-sleep or pre-sleep GH pulse windows when endogenous GH secretion is naturally elevated. Multiple-daily-administration models have also been examined, with 2-3x daily administration producing more frequent GH pulses.

For the DAC combination, weekly CJC-1295 DAC has been studied with ipamorelin administered 2-3x daily — maintaining baseline GHRH receptor stimulation while ipamorelin produces acute GH pulses on its own schedule.

Documented Research Endpoints

IGF-1 elevation — Documented increases of 200-300% above baseline with sustained DAC protocols. IGF-1 is the primary biomarker for GH axis activation in most research models.

Body composition — Research models examining extended administration documented lean mass improvements and fat mass reduction consistent with GH axis activation and downstream IGF-1 mediated protein synthesis.

GH pulse characteristics — The combined stack produces GH pulse amplitudes significantly larger than either compound alone, with preservation of normal pulsatility patterns — a key advantage over exogenous HGH which produces continuous rather than pulsatile GH elevation.

All compounds are intended strictly for laboratory and research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. For research use only per Ares Research terms.